Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
NASDAQ:THRD
THRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.18 - $16.02
Previous CloseN/A
Volume85.60K
Average Volume (3M)195.70K
Market Cap
$245.95M
Enterprise Value-$22.66M
Total Cash (Recent Filing)$271.61M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 07, 2025EPS Estimate
-0.23Last Dividend Ex-Date
Aug 06, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding45,127,796
10 Day Avg. Volume139,596
30 Day Avg. Volume195,696
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-13.55
Enterprise Value/Gross Profit1.89K
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$5.23Price Target Upside-3.68% Downside
Rating ConsensusHold
Number of Analyst Covering0
Third Harmonic Bio, Inc. News
PremiumCompany Announcements
Third Harmonic Bio Plans Nasdaq Delisting by July 31
PremiumCompany Announcements
Third Harmonic Bio Approves Liquidation and Dissolution Plan
PremiumCompany Announcements
Third Harmonic Bio Approves Key Proposals at Annual MeetingPremiumCompany Announcements
Third Harmonic Bio Reports Q1 2025 Financial Results
PremiumCompany Announcements
Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down
Bulls Say, Bears Say
Bulls Say
Financial PositionThird Harmonic ended the fourth quarter of 2024 with $285 million in cash, which is expected to support operations at least through 2026.
Program DevelopmentThe company plans to complete all Phase 2 readiness activities for THB335 by mid-year to maximize the value of the program.
Bears Say
Safety ConcernsSafety profile concerns, including reductions in hemoglobin and neutrophils, likely limit the use of higher doses going forward.
Stock DowngradeThe stock rating for THRD has been downgraded to Hold due to a lack of clarity on the development path for THB335.
Strategic UncertaintyThere is uncertainty regarding the future development of THB335 and the company's strategic direction.
Ownership Overview
24.80% Insiders
4.12% Mutual Funds
<0.01% Other Institutional Investors
65.16% Public Companies and
Individual Investors
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $3.18 and its highest was $16.02 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Third Harmonic Bio, Inc.’s market cap is $245.95M.
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 16 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Overvalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of N/A. See more information on Third Harmonic Bio, Inc. dividends here
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 45,127,796 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Currently, no hedge funds are holding shares in THRD
Third Harmonic Bio, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.23 (-3.68% Downside)
$5.23 (-3.68% Downside)
Blogger Sentiment
Bullish
THRD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.62%
12-Months-Change
Fundamentals
Return on Equity
-19.94%
Trailing 12-Months
Asset Growth
3.44%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. (THRD) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of allergic and inflammatory diseases. Leveraging its expertise in immunology and drug development, the company aims to address unmet medical needs by creating targeted therapies that modulate specific pathways involved in allergic and inflammatory responses.
Technical Analysis
Cardiff Oncology
―
Neurogene
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―